FCR-001

Unassigned

New Medicines

Transplant rejection in living donor kidney transplant recipients

Information

Advanced therapy medicinal product (ATMP)
Talaris Therapeutics
Talaris Therapeutics

Development and Regulatory status

None
None
Phase III Clinical Trials
Yes

Category

An allogeneic haematopoietic stem cell-based therapy, which includes facilitating cells from a donor. The cell therapy demonstrated induction of immune tolerance, or bone marrow chimerism, after transplantation.
In 2018/19, there were 935 living donor kidney transplants [3].
Transplant rejection in living donor kidney transplant recipients
Intravenous